Trump says Nvidia not allowed to sell advanced AI chips to China- 60 Minutes
TOKYO/ROLLE - Japanese genetic testing leader A.D.A.M. Innovations and AI healthcare technology company SOPHiA GENETICS (NASDAQ:SOPH), currently valued at $292.62 million and trading near its InvestingPro Fair Value, announced Thursday a strategic partnership to bring advanced liquid biopsy genomic testing to Japan’s cancer patients.
The collaboration, revealed at the European Society for Medical Oncology (ESMO) Congress in Berlin, will initially focus on launching MSK-ACCESS powered with SOPHiA DDM Platform. This liquid biopsy test detects genomic alterations from blood samples by analyzing circulating tumor DNA using artificial intelligence. SOPHiA GENETICS brings strong financial fundamentals to this partnership, with InvestingPro data showing the company holds more cash than debt and maintains healthy liquidity ratios.
A.D.A.M. Innovations, which has performed over 2.8 million genomic tests in its 20-year history, will conduct the testing at its Tokyo laboratory. The local processing aims to reduce turnaround times and costs for Japanese patients while supporting domestic cancer research.
The companies also plan to develop a liquid biopsy companion diagnostic test in Japan, which would help match patients with appropriate targeted therapies.
"Making precision oncology more accessible to patients in Japan is a significant milestone," said Ross Muken, President of SOPHiA GENETICS, according to the press release.
Michel Mommejat, President of A.D.A.M. Innovations, stated that "testing locally enables faster turnaround times, reduces costs, enhances patient care, and supports global CDx deployments."
A.D.A.M. Innovations, currently operating as Genesis Healthcare Co., will officially change its name on November 1, 2025.
The partnership represents an effort to expand precision medicine in Japan’s oncology sector by combining A.D.A.M.’s local market presence with SOPHiA GENETICS’ AI-powered platform technology. The company has shown impressive momentum, with a 52.67% stock return over the past six months and 7.31% revenue growth in the last twelve months. For deeper insights into SOPHiA GENETICS’ growth potential and comprehensive analysis, investors can access the full InvestingPro Research Report, available alongside 1,400+ other detailed company analyses.
In other recent news, BTIG has increased its price target for Sophia Genetics to $6.00 from $5.00, while maintaining a Buy rating. This adjustment is based on several growth indicators identified by the firm. Notably, Sophia Genetics has reported a record number of new customer signings, which is a positive development for the company. Additionally, a newly announced data partnership with AstraZeneca is expected to enhance business prospects. BTIG also noted that Sophia Genetics is doubling the average contract value on newer deals. This increase is projected to boost average selling prices and improve gross margins. These recent developments suggest the company may be nearing a significant growth phase.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.